AbbVie's New Data And Approval Test Growth And Valuation Story [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie (NYSE:ABBV) reported positive topline Phase 3 results for risankizumab (SKYRIZI) in Crohn's disease. The company also received FDA approval for an oral combination of VENCLEXTA and acalabrutinib in previously untreated chronic lymphocytic leukemia. These updates add to AbbVie's immunology and hematology-oncology portfolio and may be relevant for long term growth planning. AbbVie enters this news cycle with its shares at $234.26 and multi year returns that some investors may view as substantial, including 14.5% over the past year and 167.3% over five years. For a company of AbbVie's size, additional late stage data in Crohn's disease and a fresh FDA approval in leukemia can matter for how investors think about the breadth of the pipeline and the durability of key franchises. For you as a shareholder or prospective investor, the key questions now are how these th
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- ???????????????????? : ????????:2035????1856?9000??????????CAGR17.9%???????????????????? [CNET News]CNET News
- AbbVie: The Only Big Pharma Stock I'd Consider a Buy-and-Never-Sell [Yahoo! Finance]Yahoo! Finance
- ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTSPR Newswire
- OSE narrows pipeline focus amid Boehringer MASH collaboration retreat [Yahoo! Finance]Yahoo! Finance
- AbbVie to Present at the Leerink Partners Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 2/4/26 - Miss
ABBV
Sec Filings
- 3/6/26 - Form 4
- 3/6/26 - Form 144
- 3/6/26 - Form 4
- ABBV's page on the SEC website